Discovery of CASP8 as a potential biomarker for high-risk prostate cancer through a high-multiplex immunoassay
Abstract Prostate cancer remains the most common non-cutaneous malignancy among men in the United States. To discover potential serum-based biomarkers for high-risk prostate cancer, we performed a high-multiplex immunoassay utilizing patient-matched pre-operative and post-operative serum samples fro...
Guardado en:
Autores principales: | Shiqin Liu, Fernando Garcia-Marques, Chiyuan Amy Zhang, Jordan John Lee, Rosalie Nolley, Michelle Shen, En-Chi Hsu, Merve Aslan, Kashyap Koul, Sharon J. Pitteri, James D. Brooks, Tanya Stoyanova |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c6bfe0a2ff6e4c97bafc3c2d9739e9ab |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer
por: En-Chi Hsu, et al.
Publicado: (2021) -
A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections.
por: Lola Marqué, et al.
Publicado: (2021) -
A novel high performing multiplex immunoassay Multi-HTLV for serological confirmation and typing of HTLV infections
por: Lola Marqué, et al.
Publicado: (2021) -
An analysis and evaluation of the WeFold collaborative for protein structure prediction and its pipelines in CASP11 and CASP12
por: Chen Keasar, et al.
Publicado: (2018) -
Development and Standardization of a High-Throughput Multiplex Immunoassay for the Simultaneous Quantification of Specific Antibodies to Five Respiratory Syncytial Virus Proteins
por: Rutger M. Schepp, et al.
Publicado: (2019)